Drug Profile

Ciclosporin nanotherapeutic - Cardiol Therapeutics

Alternative Names: CTX03; Cyclosporine A nanotherapeutic - Cardiol Therapeutics

Latest Information Update: 28 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cardiol Therapeutics
Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Heart failure

Most Recent Events

28 Jun 2022 No recent reports of development identified for preclinical development in Heart-failure in Canada
13 Jun 2018 Chemical structure information added
24 May 2018 Preclinical trials in Heart failure in Canada before May 2018 (Cardiol Therapeutics pipeline, June 2018)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com